Corcept Therapeutics
CORT
98 hedge funds and large institutions have $161M invested in Corcept Therapeutics in 2015 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 30 increasing their positions, 29 reducing their positions, and 6 closing their positions.
1,804% more call options, than puts
Call options by funds: $476K | Put options by funds: $25K
300% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 6
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
23% more funds holding
Funds holding: 80 → 98 (+18)
3% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 29
34% less capital invested
Capital invested by funds: $244M → $161M (-$83M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ISL
Ingalls & Snyder LLC
New York
|
+$2.38M |
| 2 |
Morgan Stanley
New York
|
+$2.04M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.96M |
| 4 |
TIM
Thornburg Investment Management
Santa Fe,
New Mexico
|
+$1.7M |
| 5 |
Millennium Management
New York
|
+$990K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$1.44M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$1.34M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$439K |
| 4 |
RFC
Russell Frank Company
Seattle,
Washington
|
-$419K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$418K |
CORT Hedge Fund Activity: Q3 2015 in Review
98 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q3 2015, worth a combined $161M — down 34% from $244M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CORT positions and 6 closed out — a net gain of 18 holders — while 30 added to existing stakes and 29 trimmed.
The largest buyer was Ingalls & Snyder LLC, adding an estimated $2.38M. The largest seller was Invesco, exiting entirely with an estimated $1.44M sold.
- 98 institutional investors held Corcept Therapeutics (CORT) as of Q3 2015, up from 80 in Q2 2015.
- Funds reported $161M of Corcept Therapeutics stock for Q3 2015, down 34% quarter-over-quarter.
- 24 funds opened new Corcept Therapeutics positions in Q3 2015 and 6 closed out, a net change of +18 holders.
- The largest Corcept Therapeutics buyer in Q3 2015 was Ingalls & Snyder LLC, an estimated $2.38M added.
- The largest Corcept Therapeutics seller in Q3 2015 was Invesco, an estimated $1.44M sold.
Based on aggregated 13F filings for Q3 2015.